ImmunityBio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IBRX | BNTX | 4564.T | IOVA | CGON | BINV.ST | |
|---|---|---|---|---|---|---|
| Market cap | 9.46B | 22.49B | 6.94B | 3.94B | 6.00B | 240.84M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -121.8 | -16.6 | -0.8 | -44.4 | -22.4 | -0.9 |
| Price/book | -9.0 | 1.1 | 3.0 | 5.4 | 5.8 | 1.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +285.58% | −15.96% | −26.09% | +387.85% | +68.76% | −88.59% |
| Today | +7.72% | +4.35% | 0.00% | −1.47% | +5.70% | +2.09% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All IBRX news ›Expanded Use for ImmunityBio Drug
Anktiva can now treat a more common form of bladder cancer. Culver City-based immunotherapy company ImmunityBio Inc. has gained U.S. Food and Drug Administration approval for expanded use of its primary drug Anktiva to treat a more common…
ImmunityBio (IBRX) Expected to Announce Earnings on Tuesday
Posted by Mitch Edgeman on Oct 27th, 2026 IBRX opened at $7.81 on Tuesday. The company has a market cap of $8.28 billion, a P/E ratio of -8.05 and a beta of 0.02. The business’s 50-day moving average price is $8.65 and its 200-day moving…
ImmunityBio (IBRX): November ANKTIVA Trial Results Could Support Expanded FDA Filing?
ImmunityBio (IBRX) completed database lock for its 366-patient QUILT-2.005 trial evaluating ANKTIVA plus BCG in BCG-naïve bladder cancer. Topline results are expected in November 2026, with an FDA supplemental application planned for Q4…
Absci (NASDAQ:ABSI) vs. Lyell Immunopharma (NASDAQ:LYEL) Critical Comparison
Posted by Danessa Lincoln on Oct 25th, 2026 Absci (NASDAQ:ABSI – Get Free Report) and Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two…
ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nears
ImmunityBio (IBRX) shares were in focus on Wednesday after the immunotherapy company said it had completed the database lock for a 366-patient trial testing ANKTIVA plus BCG in patients with BCG-naïve non-muscle invasive bladder cancer…
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
The database lock follows the completion of the data review, verification, and reconciliation of all 366 randomized patients, allowing the final efficacy analysis to proceed. The trial is designed to determine whether adding ANKTIVA to…
ImmunityBio: FDA expands ANKTIVA bladder cancer use
VivoPower Signs Definitive Heads of Agreement with Open Innovation AI to Develop Secure Sovereign AI Data Centers Across the Nordics, Mainland Europe, the GCC and selective countries in Asia BioCryst Announces U.S. FDA Approval of…
More from 1 other outlet
ImmunityBio director Simon sells 25,000 shares
Tesla Releases Third Quarter 2026 Financial Results QuantumScape Announces Plans for 100 MWh Solid-State Battery Production Line for AI Data Centers, Aerospace and Defense Alpha Modus Announces $7.25 Million Registered Direct Offering of…
ImmunityBio director Cheryl Cohen sells 81,056 shares
Tesla Releases Third Quarter 2026 Financial Results QuantumScape Announces Plans for 100 MWh Solid-State Battery Production Line for AI Data Centers, Aerospace and Defense Alpha Modus Announces $7.25 Million Registered Direct Offering of…
IBRX Stock Rattled As Legal Probes Target ImmunityBio
ImmunityBio Inc. stocks have been trading down by -6.05 percent after clinical trial concerns sparked heightened investor risk aversion. ImmunityBio (IBRX) is not trading like a stable, cash-rich giant. It’s acting like a high-risk biotech…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktwits.com7
- themarketsdaily.com5
- stocktitan.net4
- defenseworld.net3
- tradingview.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 35 articles, not a forecast.